Hepion Pharmaceuticals to Present at NASH-TAG 2024
January 03, 2024 17:15 ET
|
Hepion Pharmaceuticals, Inc.
EDISON, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic...
Visiox Pharmaceuticals, Inc., a Commercial-Stage Biopharmaceutical Company to be Listed on Nasdaq Through a Business Combination with PowerUp Acquisition Corp.
December 27, 2023 08:01 ET
|
PowerUp Acquisition Corp.
Tarrytown, NY and New York, NY, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Visiox Pharmaceuticals, Inc. (“Visiox” or the “Company”), a commercial-stage biopharmaceutical company, and PowerUp Acquisition...
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until January 12, 2024
December 15, 2023 16:15 ET
|
Aridis Pharmaceuticals, Inc.
LOS GATOS, Calif., Dec. 15, 2023 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (OTC QB: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective...
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
December 14, 2023 07:50 ET
|
Aeterna Zentaris Inc
TORONTO and EDMONTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna”) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) (“Ceapro”), two innovative...
Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management Changes
December 07, 2023 08:00 ET
|
Hepion Pharmaceuticals, Inc.
Restructuring program purpose is to preserve capital and optimize clinical development program Management plans to continue to evaluate its Phase 2b ASCEND-NASH clinical trial taking in account...
Biocon Biologics Successfully Completes Integration of Viatris’ Biosimilar Business in 31 Countries in Europe
November 30, 2023 05:00 ET
|
Biocon Biologics
BENGALURU, India, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced that the integration of the Viatris’...
Timber Pharmaceuticals Receives Court Approval of All “First Day” Motions to Support Business Operations & Discloses Communication From NYSE American
November 28, 2023 17:21 ET
|
Timber Pharmaceuticals
WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American: TMBR), a clinical-stage biopharmaceutical company focused on the development and...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024
November 21, 2023 06:00 ET
|
Greenwich LifeSciences, Inc.
STAFFORD, Texas, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an...
Palisade Bio Reports Third Quarter 2023 Financial Results and Provides Business Outlook
November 10, 2023 08:05 ET
|
Palisade Bio, Inc.
– Transformational transaction jumpstarts development pipeline into high-value inflammatory bowel disease (IBD) market – Lead program, PALI-2108, oral prodrug therapy for the treatment...
Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance
November 03, 2023 16:30 ET
|
Scinai Immunotherapeutics Ltd.
JERUSALEM, Nov. 03, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative...